ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine & Initial Data from Phase 1b FORWARD...

Conference Call to be Held at 8 a.m. ET on Monday, September 30

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full data and additional exploratory analyses from the Phase 3 FORWARD I study evaluating mirvetuximab soravtansine compared to chemotherapy in women with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress to be held from September 27 to October 1, 2019 in Barcelona, Spain. Initial safety and overall response rate data from the Phase 1b FORWARD II triplet study evaluating mirvetuximab in combination with carboplatin and Avastin® (bevacizumab) in patients with recurrent platinum-sensitive ovarian cancer will also be featured in a poster at the congress.

Oral Presentation Details

• Title: “FORWARD I (GOG 3011): A Phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)” (Abstract #992O)
• Date: September 29, 2019
• Time: 8:30 a.m. CEST/2:30 a.m. EDT
• Lead Author: Kathleen Moore M.D., University of Oklahoma Health Sciences Center, Oklahoma City, OK

Poster Details

• Title: “Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a Phase 1b study in patients with ovarian cancer” (Abstract #1028P)
• Date: September 29, 2019
• Time: 12:00 p.m. CEST/6:00 a.m. EDT
• Lead Author: David M. O’Malley M.D., James Cancer Center and The Ohio State University Wexner Medical Center, Columbus, OH

Additional information and full abstracts can be found at www.esmo.org.

CONFERENCE CALL INFORMATION ImmunoGen will hold a conference call at 8 a.m. ET on Monday, September 30, 2019. Dial-in details to follow.

ABOUT MIRVETUXIMAB SORAVTANSINE Mirvetuximab soravtansine (IMGN853) is the first folate receptor alpha (FRα)-targeting ADC. It uses a humanized FRα-binding antibody to target the ADC specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.

ABOUT IMMUNOGEN ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

AVASTIN® is a registered trademark of Genentech, Inc.

This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen’s expectations related to: the occurrence, timing, and outcome of potential pre-clinical, clinical, and regulatory events related to the Company’s product candidates. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen’s actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and results of communications with FDA, risks and uncertainties related to the execution of the restructuring of the Company’s operations, the Company’s ability to control future spending to enable it to fund its remaining operations through the release of top-line results from the upcoming mirvetuximab pivotal study, as well as the risks and uncertainties inherent in the Company’s development programs, including clinical studies and regulatory processes, their timings and results. A review of these risks can be found in ImmunoGen’s Annual Report on Form 10-K for the year ended December 31, 2018 and other reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005315/en/

INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O’Konek 781-895-0600 [e-mail] OR FTI Consulting Robert Stanislaro 212-850-5657 [e-mail]